SF Yan, R Ramasamy, AM Schmidt - Journal of Molecular Medicine, 2009 - Springer Abstract The actors in the pathogenesis of diabetes and its complications are many and
multifaceted. The effects of elevated levels of glucose are myriad; among these is the generation
of advanced glycation end products (AGEs), the products of nonenzymatic glycoxidation ... Cited by 5 - Related articles - All 3 versions
- ►cardiovascres.org L Gao, GE Mann - Cardiovascular Research, 2009 - cardiovascres.oxfordjournals.org Oxidative stress mediated by hyperglycaemia-induced generation of reactive oxygen species
(ROS) contributes significantly to the development and progression of diabetes and related vascular
complications. NAD(P)H oxidase has been implicated as the major source of ROS ... Cited by 8 - Related articles - All 6 versions
SF Yan, SD Yan, R Ramasamy, AM Schmidt - Annals of Medicine, 2009 - informahealthcare.com The multiligand receptor RAGE (receptor for advanced glycation end-products) is emerging as
a central mediator in the immune/inflammatory response. Epidemiological evidence accruing
in the human suggests upregulation of RAGE's ligands (AGEs, S100/calgranulins, high ... Cited by 3 - Related articles - All 3 versions
KAM Jandeleit-Dahm, A Calkin, C Tikellis, M … - Current Opinion in …, 2009 - journals.lww.com Peroxisome proliferator activated receptors (PPARs) are ligand-dependent transcription factors
that mediate a range of important metabolic functions in the human body. Activation of PPAR
is able to modulate gene transcription by transactivation, transrepression or corepression ... Cited by 3 - Related articles - All 3 versions
SD Yan, A Bierhaus, PP Nawroth, DM Stern - Journal of Alzheimer's Disease, 2009 - IOS Press Abstract. Receptor for Advanced Glycation Endproducts (RAGE) is a multiligand member of the
immunoglobulin superfamily of cell surface molecules which serves as a receptor for
amyloid-β peptide (Aβ) on neurons, microglia, astrocytes, and cells of vessel wall. ... Cited by 5 - Related articles - All 2 versions
MM Averill, KE Bornfeldt - Current Diabetes Reports, 2009 - Springer Type 1 and type 2 diabetes both accelerate cardiovas- cular disease, yet the triggers are likely
different for the two types of diabetes. Results from large-scale clinical trials suggest that intense
blood glucose con- trol can reduce cardiovascular events many years later in patients ... Cited by 2 - Related articles - All 2 versions
- ►dvdres.com [PDF] JB Lindsey, F Cipollone, SM Abdullah, DK … - Diabetes and Vascular …, 2009 - dvdres.com Abstract Disorders of glucose metabolism are associated with increased risk for cardiovascular
disease (CVD) complications, including coronary, periph- eral and cerebral arterial disease,
that account for the majority of morbidity and mortality among patients with diabetes ... Cited by 1 - Related articles - All 7 versions
ME Cooper - Pediatric Diabetes, 2009 - pt.wkhealth.com Over the last decade, the ongoing follow up of the original The Diabetes Control and Complications
Trial (DCCT) cohort, known as the Epidemiology of Diabetes Interventions and Complications
(EDIC) study, has revealed that individuals who were randomized initially to the more ... Related articles - All 5 versions
S Muhammad, A Bierhaus, M Schwaninger - Journal of Alzheimer's Disease, 2009 - IOS Press Abstract. A morphological hallmark of Alzheimer's disease (AD) is the deposition of amyloid-β
peptide in plaques and along blood vessels. As several lines of evidence suggest that vascular
dysfunction contributes to AD, the pathophysiology of diabetic vasculopathy and stroke ... Related articles - All 2 versions
AMD Watson, J Li, C Schumacher, M de Gasparo, B … - Diabetologia - Springer Abstract Aims/hypothesis There is convincing evidence that the endothelin system contributes
to diabetic nephropathy and cardiovascular disease. This study aimed to assess the effects of
the non-peptidergic endothelin receptor A (ETA) antagonist avosentan in a mouse model ...
